P5 Health Ventures

David Eigen is the sole named team member on the firm's website and appears to drive both investment decisions and strategic direction. P5 has not disclosed a broader investment committee or additional partners. Allocators conducting diligence should expect a centralized decision-making structure.

The firm's sourcing model appears to draw on its public thesis-building efforts, including the 'P5 Protocols' podcast series that features clinicians and researchers in functional, metabolic, and systems medicine. By cultivating a network of practitioners who operate at the edge of conventional care protocols, P5 positions itself to see technologies — particularly in diagnostics and AI-driven chronic-disease management — before they enter mainstream venture pipelines.

P5 is structured as an asset manager and private equity firm, not a family office. It pursues a venture capital strategy — primarily Seed through Series B — with an explicit platform-building vision that involves assembling minority and majority ownership positions. There is no public indication of family-office or single-LP capital.

All publicly available information points to direct investing only. The firm describes taking minority and majority ownership positions in individual companies and building a platform from those positions. There is no mention of fund-of-funds commitments, LP investments in external venture funds, or co-investment club structures.

P5 states it is primarily focused on Seed through Series B companies that are either near revenue generation — within 18 months — or already generating revenue, with clear exit paths. The portfolio includes startups developing core IP in diagnostics, AI, and disease management, consistent with an early-stage venture posture.

The firm does not publish a negative sector list. Its disclosed areas of interest — diagnostics, biomarkers, chronic disease management, digital twins, AI-enabled decision support, consumer-driven healthcare, longevity, and value-based care — suggest a deliberate avoidance of acute-care infrastructure, inpatient services, and traditional biopharma drug development.

No philanthropic foundation, donor-advised fund, or impact-investing vehicle has been disclosed. The firm's mission — 'Enable the prevention of and healing from chronic and infectious diseases, ending misery and saving lives' — is pursued through its for-profit investment activities and public content, without an identifiable nonprofit arm.